K-numberK250270
Device nameLuja Set
ApplicantColoplast Corp.
Product codeEZD
Device classClass II
Decision dateApr 17, 2025
DecisionSubstantially Equivalent
Regulation876.5130
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The Luja Set is an intermittent, ready-to-use, sterile urological catheter with an integrated urine collection bag. It is indicated for male patients (adults and pediatric above age 1 year) with urine retention or post-void residual volume due to neurogenic and non-neurogenic voiding dysfunction. The hydrophilic-coated catheter with a straight tip is inserted into the urethra to allow urine to drain into the attached collection bag.

Technological characteristics

The subject device shares nearly identical technological characteristics with the predicate Luja Coudé, including the same regulation, classification, materials (polyurethane catheter with PVP-based hydrophilic coating), sterilization method (e-beam), and shelf life (2 years). The key differences are the straight tip configuration (versus the predicate's flexible curved tip) and the integrated collection bag design. Available sizes are CH10, CH12, CH14, and CH16, compared to the predicate's CH8–CH18 range.

Test standards cited

ISO 20696:2018 (Sterile urethral catheters for single use) and ASTM F623-19 (Standard performance specification for Foley Catheter). Testing was performed on final, finished, and sterilized devices to verify acceptance criteria.

Substantial equivalence argument

The subject device is substantially equivalent because it shares the same intended use (intermittent catheterization), indications (urine retention and post-void residual volume management), regulation (21 CFR 876.5130), and technological platform as the predicate. Although it differs in tip configuration (straight versus curved) and includes an integrated collection bag, these design differences do not alter the fundamental safety and effectiveness profile. Risk assessment identified flow rate and kink stability as the key performance risks, and bench testing using both the predicate and reference device (SpeediCath Flex Set) demonstrated the subject device meets pre-determined acceptance criteria for these parameters, establishing that it is as safe and effective as the predicate.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →